62 Views | 19 Downloads
Mehmet Asim Bilen, mehmet.a.bilen@emory.edu
TZ and SM drafted the editorial. MB and KB edited the manuscript. All authors contributed to this work and gave approval to the final version.
MB has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi, and his institution has received grants from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer for work performed outside of the current study. KB has acted as a paid consultant for and/or as a member of the advisory boards of LCFA-BMS-IASLC for Young Investigator Award, Alpine Biosciences, Aravive, Astrazeneca, Aveo, BMS, Exelexis, Merck, Sanofi, and Seagen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
© 2023 Zhuang, Mustafa, Beckermann and Bilen